Arineta Taps Veteran Executive Einav Ehre as Interim CEO to Drive Continued Growth of its Cardiac CT Solutions

Seasoned finance and operations leader will focus on expanding cardiac CT access for clinics and cardiology practices nationwide.
  • The founding member of Arineta will continue his roles as Chief Operating Officer and Chief Financial Officer in addition to his new appointment.
  • As CEO, Ehre aims to reaffirm Arineta’s goal of improving access to dedicated cardiac CT through small footprint, affordable, high-powered scanners.
  • Arineta’s SpotLight and SpotLight Duo are deployed across the top cardiology practices, imaging centers, and hospital systems in the U.S.

Caesarea, Israel – Feb. 3, 2025Arineta, a leader in advancing cardiovascular imaging solutions, today announced the appointment of Einav Ehre by its board of directors as interim Chief Executive Officer, effective immediately. Ehre will continue to serve in his current roles as the company’s Chief Operating Officer and Chief Financial Officer.


Ehre is one of Arineta’s founding executives and a leader at the company since 2007. Over nearly two decades, he has played an instrumental role in scaling Arineta’s global operations, building the company’s organizational structure, and overseeing finance, accounting, HR, operations, strategic planning, and executive leadership across the U.S., Israel, and China.

As interim CEO, Ehre will reinforce Arineta’s strategy to broaden access to cardiac CT imaging, particularly for clinics and smaller cardiology practices. His priorities include advancing the company’s commitment to AI-guided innovation, strengthening reimbursement pathways, and helping providers adopt advanced CT technology in a financially sustainable way. With a focus on the growing role of AI in improving efficiency, Ehre is dedicated to streamlining the integration of advanced image analysis while maintaining high standards for image quality and clinical value. He also remains focused on supporting the organization and its employees as the company moves into its next phase of growth.


“With this technology and the responsible use of AI, I believe the team at Arineta will continue to be a leader in changing how heart disease is managed and ensuring care is accessible to all,” said Ehre. “Intervention shouldn’t happen only after adverse events, and if we can help clinicians identify risk sooner, it becomes a disease we can control.”


Arineta’s flagship systems, SpotLight and SpotLight Duo, are the world’s first dedicated cardiovascular CT scanners, designed specifically for single-beat, whole-heart imaging. By reducing the physical footprint and cost typically associated with cardiac CT, Arineta is improving access to advanced cardiac diagnostics, allowing for broader use by providers to reach more patients.